Navigation Links
Masimo Reports Second Quarter 2007 Financial Results
Date:9/19/2007

mpany's performance (in thousands, except share data):

Three Months Ended Six Months Ended

June 30, June 30,

2006 2007 2006 2007

Numerator:

GAAP net income $3,864 $2,798 $53,391 $5,110

Preferred stock dividend (1) - - 58,571 -

Accretion of preferred

stock (2) 1,956 1,956 4,073 3,913

Undistributed income

attributable to preferred

stockholder (3) 8,102 5,802 42,584 10,630

Non-GAAP net income 13,922 10,556 158,619 19,653

Denominator:

GAAP Weighted average number

of shares - Diluted 20,301,629 20,732,014 19,975,936 20,699,111

Weighted average

preferred shares (4) 34,612,503 34,612,503 34,612,503 34,612,503

Non-GAAP Weighted average

number of shares -

Diluted 54,914,132 55,344,517 54,588,439 55,311,614

Earnings per share - Diluted:

GAAP earnings per share $0.19 $0.13 $2.67 $0.25

Adjustments to if

converted method 0.06 0.06 0.24 0.11

Non-GAAP earnings per share $0.25 $0.19 $2.91 $0.36

Adjustments:

(1) Under the if converted method, no shares of preferred stock would

have been outstanding, therefore no dividends would have been

recorded specifically for preferred shareholders.

(2) Under the if converted method, no shares of preferred stock would

have been outstanding; therefore no allocation of undistributed

income to preferred stockholders would have been made.

(3) Under the if converted method, no shares
'/>"/>

SOURCE Masimo Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Hardware, and Biocontent. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:9/16/2014)... film for radar domes have now refined the technology ... , The new work by Rice chemist James Tour ... to skyscrapers free of ice and fog while retaining ... technology was introduced this month in the American Chemical ... , The material is made of graphene nanoribbons, atom-thick ...
(Date:9/16/2014)... DURHAM, N.C. , Sept. 16, 2014 /PRNewswire-USNewswire/ ... and oldest entrepreneurial support organization in the country, ... Innovators Report . It ... North Carolina startups in ... sectors drew more global investment from a variety ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... 2008 - Vol. 299. No. 8: ,Venous Thromboembolism and ... Administration for the Treatment of Cancer-Associated ... believes that,the conclusions of a study published in the ... Medical Association (JAMA) by Bennett, et al, do,not provide ...
... 26 CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported ... 31, 2007., For the quarter ended December 31, 2007, ... per share. This compares to a net loss of,$68.1 million, ... and $34.2,million, or $0.58 per share, for the prior quarter ...
... REINACH, Switzerland, February 26 Arpida Ltd.,(SWX: ARPN) today ... (NDA) for intravenous iclaprim in its first indication,complicated Skin ... next few weeks., Arpida has agreed with the ... in a rolling process. Using a ,rolling NDA, allows ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3
(Date:9/16/2014)... rock hit the Yukatan peninsula near the site of the ... of TNT. It left a crater more than 150 km ... are widely accepted to have wiped out the dinosaurs and ... happened to the plants on which the dinosaurs fed? , ... Arizona reveals that the meteorite impact that spelled doom for ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... Three years after the Hesperides vessel returned to Spain ... researchers have an increasingly clear picture of how the ... Specifically, the input of pollutants from the atmosphere is ... the most remote areas of the planet, and it ... findings are presented this week in CSIC Residence for ...
Breaking Biology News(10 mins):Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... , May 30, 2013  Chiltern International Limited (Chiltern), a global ... Barbee to the position of Vice President, Global Biometrics. ... Chiltern stated: "We are extremely pleased to announce the promotion of ... to VP of Global Biometrics. In this role, Alecia will have ...
... for final exams might want to wait before pulling ... as their neurons are concerned. Carnegie Mellon University neuroscientists ... during which repeated exposure to a stimulus shrinks synapses. ... of the Journal of Neuroscience . It,s ...
... summit in Lough Erne, Northern Ireland, the German National ... science academies of the G8 member states and five ... state and government of the eight leading industrialised nations ... immediate future: drug-resistant infectious agents and sustainable development. The ...
Cached Biology News:Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics 2Carnegie Mellon neuroscientists discover new phase of synaptic development 2The German National Academy of Sciences Leopoldina makes recommendations for the G8 summit 2
... screening, low melting point agarose where separation ... recommended for separation of nucleic acids less ... products. Micro ABgarose is also suited to ... blotting techniques. At a 3% concentration, Micro ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
... Abpromise for all tested applications). ... derived from within residues 1 - 100 of ... is proprietary) (Peptide available as ... ID: 5453 Swiss Protein ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Biology Products: